The Role of Maintenance Therapy for the Treatment of Multiple Myeloma

Please Log In or Register to continue.

Release Date: November 14, 2018
Expiration Date: November 14, 2019

Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Autologous stem cell transplant (SCT) continues to be the standard of care for eligible patients with multiple myeloma (MM) who can tolerate high-dose melphalan therapy. Although other treatment options are available to avoid relapse, the concept of continuous therapy after autologous SCT has been introduced and continues to be investigated in studies. In this activity, Dr. Sarah Holstein compares consolidation chemotherapy with maintenance treatment approaches from recent research on the efficacy and safety of new and emerging combinations. Dr. Holstein’s presentation focuses on maintenance therapy in the post-autologous SCT setting.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the importance of maintenance therapy in the treatment of multiple myeloma
  • Compare and contrast the efficacy and safety of new and emerging agents for treatment of multiple myeloma in the maintenance setting
  • Incorporate evidence-based recommendations when determining the appropriate maintenance treatment for patients with multiple myeloma

Agenda

The Role of Maintenance Therapy for the Treatment of Multiple Myeloma – Sarah A. Holstein, MD, PhD

Instructions for Participation and Credit

This activity is eligible for credit through November 14, 2019. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Sarah A. Holstein, MD, PhD
Associate Professor
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Dr. Sarah Holstein received her medical degree and PhD in pharmacology from the University of Iowa Carver College of Medicine. She continued her postgraduate studies there with a residency in internal medicine and a fellowship in hematology/oncology. She is currently an Associate Professor in the Division of Oncology and Hematology, Department of Internal Medicine, at the University of Nebraska Medical Center in Omaha.

Dr. Holstein holds board certification in internal medicine, hematology, oncology, as well as by the National Board of Physicians and Surgeons. She is a member of the American College of Physicians, American Society of Hematology, American Society of Clinical Oncology, American Society for Clinical Pharmacology and Therapeutics, and the International Myeloma Society of Hematologic Oncology. In addition, Dr. Holstein is a member of the Alliance Multiple Myeloma Committee and the NCCN Multiple Myeloma Panel. She has written numerous peer-reviewed research articles as well as review articles and book chapters, and is an ad hoc reviewer for dozens of peer-review journals.

As a physician-scientist who specializes in the treatment of multiple myeloma, Dr. Holstein’s laboratory is focused on gaining a better understanding of the pathophysiology and the development of novel therapeutic agents for this disease. She is an active clinical investigator, and has been involved in clinical trials for newly diagnosed myeloma, relapsed/refractory disease, as well as in the post-transplant maintenance setting.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-18-030-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Sarah Holstein has received honoraria as a consultant from Celgene Corporation.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology

©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.